erbB-2 Antibody | 5153

erbB-2 Antibody | 5153 | Gentaur UK, US & Europe Distribution

Host: Chicken

Reactivity: Human, Mouse, Rat

Homology: N/A

Immunogen: erbB-2 antibody was raised against a 19 amino acid synthetic peptide near the carboxy terminus of human erbB-2.
The immunogen is located within the last 50 amino acids of erbB-2.

Research Area: Cancer

Tested Application: E, WB, IHC-P, IF, IP

Application: erbB-2 antibody can be used for detection of erbB-2 by Western blot at 1 - 2 μg/mL. Antibody can also be used for immunohistochemistry starting at 2.5 μg/mL. For immunofluorescence start at 20 μg/mL.
Antibody validated: Western Blot in rat samples; Immunohistochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.

Specificiy: N/A

Positive Control 1: Cat. No. 1464 - Rat Liver Tissue Lysate

Positive Control 2: Cat. No. 10-201 - Human Liver Tissue Slide

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: N/A

Validation: N/A

Isoform: N/A

Purification: erbB-2 Antibody is affinity chromatography purified via peptide column.

Clonality: Polyclonal

Clone: N/A

Isotype: IgY

Conjugate: Unconjugated

Physical State: Liquid

Buffer: erbB-2 Antibody is supplied in PBS containing 0.02% sodium azide.

Concentration: 1 mg/mL

Storage Condition: erbB-2 antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Alternate Name: erbB-2 Antibody: NEU, NGL, HER2, TKR1, CD340, HER-2, MLN 19, HER-2/neu, MLN19, NEU, Receptor tyrosine-protein kinase erbB-2, Metastatic lymph node gene 19 protein

User Note: Optimal dilutions for each application to be determined by the researcher.

BACKGROUND: erbB-2 Antibody: The ErbB family consists of four closely related tyrosine kinase receptors that act as potent mediators of normal cell growth and development. Aberrant expression or function of one or more of these receptors can play a major role in the development and evolution of cancer. ErbB-2, also known as HER2, has been implicated in the evolution of both breast and gastric cancers, and is evident in other cancer types such as ovarian and salivary gland tumors. ErbB-2 possesses an active tyrosine kinase domain, but no direct ligand has been identified yet. ErbB-2 is the preferred binding partner to the other members of the ErbB family and is thought to act primarily through the Ras-MAPK, PI3k-PKB/Akt, and PLC-PKC signaling pathways. Numerous anti-cancer strategies have been employed against erbB-2, such as antibody-based therapies to prevent ligand binding or receptor activation through dimerization, antibody-dependent cell mediated cytotoxicity, in addition to direct kinase inhibition to prevent molecular activation/downstream signaling.